TEAD Inhibitor Dosing Regimen for Kidney Toxicity Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TEAD inhibitors face challenges with kidney toxicity as a safety concern, particularly with long-term treatment, necessitating a dosing regimen that balances efficacy with reduced adverse side effects.
Innovation Solution
Administering a TEAD inhibitor on each of the first 3 days of a 7-day treatment cycle, with at least two treatment cycles, to reduce kidney toxicity while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous daily dosing of TEAD inhibitor is administered, then therapeutic efficacy is maintained, but kidney toxicity increases
Solution Approach 1:
The patent implements periodic dosing by administering the TEAD inhibitor only on days 1, 2, and 3 of each 7-day treatment cycle, creating a pulsing dosing pattern with 4 days off between treatment cycles. This periodic administration maintains therapeutic efficacy while allowing kidney recovery periods, thereby reducing cumulative kidney toxicity compared to continuous daily dosing.
Solution Approach 2:
The treatment regimen is segmented into distinct treatment cycles of 7 days, with each cycle containing only 3 days of active drug administration. This segmentation divides the continuous treatment into discrete intervals, allowing the kidneys to recover during the non-administration periods while still achieving cumulative therapeutic effect over multiple cycles.
2Object-affected harmful factors
If TEAD inhibitor dosing is reduced to lower kidney toxicity, then adverse side effects decrease, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent ensures continuity of useful action by designing multiple treatment cycles (at least two cycles) where the drug is administered on days 1-3 of each cycle. This repeated periodic administration maintains cumulative therapeutic exposure and sustained efficacy while the 4-day breaks between cycles provide kidney recovery time, thus preserving therapeutic action while reducing toxicity.
Data Source
AI summary
The invention relates to a TEAD inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, wherein the TEAD inhibitor is administered on each of the first 3 days of a 7 day treatment cycle, and wherein the treatment comprises at least two treatment cycles.